This site is intended for health professionals only

At the heart of general practice since 1960

pul jul aug2020 cover 80x101px
Read the latest issue online

Independents' Day

Paper of the Day - Basal-bolus insulin preferred after glargine

Patients with type 2 diabetes are more likely to hit a HbA1c target of 7% if they move on to a basal/bolus therapy – rather than prandial premixed therapy – after initial treatment with glargine.

US researchers randomly assigned 374 patients previously treated with glargine plus oral agents to receive either bedtime glargine plus mealtime lispro or 50/50 lispro mix three times a day with meals.

After 24 weeks average HbA1c was lower with the basal/bolus regime – 6.78% versus 6.95% with the prandial premixed. Significantly more patients achieved a target of less than 7% with the basal/bolus therapy – 69% versus 54%. But the difference was not significant for 6% or 7.5% targets. Rates of hypoglycamia were similar for both groups.

The authors say that although noninferiority of prandial premixed therapy to basal/bolus therapy was not demonstrated, findings for HbA1c reduction, percentage of patients achieving HbA1c targets, hypoglycemia, and number of required injections should be considered in the individual decision-making process of advancing insulin replacement in type 2 diabetes

Diabetes Care 2008; 31: 20-25.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say